Amgen Inc. (NASDAQ:AMGN) Shares Sold by Bank of New Hampshire

Bank of New Hampshire lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 2.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,563 shares of the medical research company’s stock after selling 34 shares during the quarter. Bank of New Hampshire’s holdings in Amgen were worth $504,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Strategic Financial Concepts LLC purchased a new stake in Amgen during the 2nd quarter worth $26,000. Hershey Financial Advisers LLC bought a new position in Amgen during the 2nd quarter worth $30,000. nVerses Capital LLC bought a new stake in Amgen in the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC bought a new position in Amgen in the 2nd quarter worth approximately $33,000. Finally, FSA Wealth Management LLC increased its holdings in shares of Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMGN. Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Friday, September 27th. They set an “overweight” rating and a $405.00 price objective for the company. Robert W. Baird reissued an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. Argus boosted their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Morgan Stanley dropped their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Finally, Oppenheimer reissued an “outperform” rating and issued a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $326.30.

Amgen Price Performance

Shares of NASDAQ AMGN traded down $2.21 during midday trading on Monday, hitting $317.45. 1,261,193 shares of the company’s stock were exchanged, compared to its average volume of 2,488,611. The company has a market cap of $170.29 billion, a price-to-earnings ratio of 45.35, a PEG ratio of 2.98 and a beta of 0.61. The business’s fifty day moving average price is $327.28 and its two-hundred day moving average price is $309.48. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.00 EPS. As a group, research analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.84%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.